Elderly and younger patients with non-small cell lung cancer (NSCLC) derive similar benefit from second-line chemotherapy: A retrospective subset analysis of second-line chemotherapy trials conducted from the Hellenic Cooperative Research Group (HORG).

Sofia Agelaki,Dora Hatzidaki,Lampros Vamvakas,Athanasios G. Pallis,A. Karampeazis,A Agelidou,M. Agelidou,Vassilis Chandrinos,Aristidis Polyzos,Vassilis Georgoulias

Elderly and younger patients with non-small cell lung cancer (NSCLC) derive similar benefit from second-line chemotherapy: A retrospective subset analysis of second-line chemotherapy trials conducted from the Hellenic Cooperative Research Group (HORG).

2017

Sofia Agelaki
Dora Hatzidaki
Lampros Vamvakas
Athanasios G. Pallis
A. Karampeazis
A Agelidou
M. Agelidou
Vassilis Chandrinos
Aristidis Polyzos
Vassilis Georgoulias

7564 Background: Elderly patients (pts) achieve a similar survival benefit, with acceptable toxicity, from first-line chemotherapy for the treatment of advanced NSCLC compared with their younger co...

Keywords:

non-small cell lung cancer (NSCLC)
Toxicity
Pathology
Oncology
Subset Analysis
Medicine
Internal medicine
Chemotherapy
second line chemotherapy
survival benefit
cooperative research

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations